Alliance Pharma welcomes Martin Sutherland to its Board as Independent Director and announces Richard Jones named to Senior Independent Director

– UK, Chippenham –  Alliance Pharma plc (LON: APH), the international healthcare group, today announced the appointment of Martin Sutherland to its Board as an Independent Non-Executive Director, with immediate effect.

The company also announces the appointment of the current Board member, Richard Jones, as Senior Independent Director with immediate effect.

“I am delighted to welcome Martin Sutherland to the Board and look forward to his contribution to support the delivery of our growth strategy. Martin will bring significant additional expertise from his experience as a company director and in senior executive leadership roles. The Board will also benefit from his 30 years’ experience in managing global businesses and delivering growth, said Board Chair, David Cook.

He added, “I am also pleased to appoint Richard Jones as our first Senior Independent Director. Richard will help support and expand our stakeholder engagement program, building on his extensive experience in capital markets and leveraging his strong networks with shareholders.”

About Martin Sutherland

 Martin Sutherland is a senior executive with over 30 years of experience in global businesses. He is currently a NED at FTSE-listed Forterra plc and Reliance action ltd. Forterra is a leading UK manufacturer of essential clay and concrete building products. Martin joined the Board of Forterra in 2017 and sat on the Nomination, Remuneration, Audit, and Risk & Sustainability committees. Reliance acsn ltd is a privately held specialist cyber security business, a company which he joined in 2020 as CEO and helped to drive a doubling of revenues in two years. Martin stepped down as CEO to become NED in January 2023.

Martin Sutherland was CEO of De La Rue plc between 2014 and 2019 and previously held various roles at Detica plc, becoming Managing Director in 2008 on its acquisition by BAE Systems plc. Martin has a proven track record of delivering growth through new product innovation, market diversification, and international expansion. We believe that Martin’s experience will bring a unique perspective to complement the strong consumer healthcare knowledge already present on the Board.

Following its annual review, the Board has decided to appoint Richard Jones, current NED, and Chair of the Audit & Risk Committee, as Senior Independent Director

About Alliance

Alliance Pharma plc is an international healthcare group. Our purpose is to improve the lives of consumers and patients by making available a range of clinically valuable healthcare products.

Our core focus is on marketing consumer healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor, and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximizing the value of our brands.

For more information: https://www.alliancepharmaceuticals.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.